Enterococcus faecalis infection

Summary

Enterococcus faecalis infection (MONDO:0005121) is a disease and 7 clinical trials. Top therapeutic interventions include chlorhexidine and nitrofurantoin. A subtype of Enterococcus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Enterococcus faecalis infection
Mondo ID	MONDO:0005121
EFO	EFO:0000780
UMLS	C0948752
MedGen	1843390
Is cancer (heuristic)	no

Also known as: Enterococcus faecalis caused disease or disorder · Enterococcus faecalis disease or disorder · Enterococcus faecalis infectious disease

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › Enterococcus infectious disease › Enterococcus faecalis infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06815549	PHASE3	NOT_YET_RECRUITING	An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis
NCT06533215	Not specified	RECRUITING	Antimicrobial Efficacy of Nano-Based ICM on E.F
NCT06833593	Not specified	RECRUITING	Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
NCT04070820	Not specified	UNKNOWN	Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study
NCT04978545	Not specified	COMPLETED	The Effect of Ca(OH)2 in Apical Periodontitis
NCT05690763	Not specified	COMPLETED	Quantitative Assessment of the Efficacy of Two Irrigation Activation Systems
NCT05718596	Not specified	COMPLETED	Quantitative Assessment of the Efficacy of Sweeps Laser Activation Systems

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHLORHEXIDINE	4	1
NITROFURANTOIN	4	1